IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) reported its financial results late Thursday for the third quarter that ended September 30, 2022.

Dr. Horst G. Zerbe, CEO of IntelGenx called the third quarter a “productive one” for IntelGenx, marked by the achievement of business milestones. “Our ongoing BUENA trial reached the halfway patient enrollment mark, while our partnership with Chemo resulted in the assignment of a GDUFA date during the second quarter of next year,” Dr. Zerbe said.

“Subsequent to quarter end, we achieved a significant milestone with Atai’s commencement of the first-ever in-human clinical study of a psychedelic administered via oral film. We are looking forward to the first half of 2023, …

Full story available on